Presidential Adviser Gibbons Battles Capitol Hill To Save Research Investments From The Budget Ax

Research Investments From The Budget Ax Editor's Note: It has been two years since President Bill Clinton appointed nuclear physicist John H. Gibbons to be director of the Office of Science and Technology Policy (OSTP). Since then, Gibbons appears to have largely contented himself with the nuts- and-bolts work of analyzing complex issues and advising the president on policy options. In many ways, Gibbons was replicating in the executive branch the role he played during the previous dozen years

Written byFranklin Hoke
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

Research Investments From The Budget Ax Editor's Note: It has been two years since President Bill Clinton appointed nuclear physicist John H. Gibbons to be director of the Office of Science and Technology Policy (OSTP). Since then, Gibbons appears to have largely contented himself with the nuts- and-bolts work of analyzing complex issues and advising the president on policy options. In many ways, Gibbons was replicating in the executive branch the role he played during the previous dozen years as director of the congressional Office of Technology Assessment (OTA). However, Republican budget proposals early this year have targeted OTA and other programs for abolishment, as well as suggesting sharp, across-the-board cuts at agencies involved in research. Thus, Gibbons has become a more active advocate for government support of science and technology, speaking at more visible venues and appearing more frequently in the press. "Ignorance is not a sound public policy," ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies